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Special AT-rich sequence-binding protein 1 (Satb1)
governs genome-wide transcriptional programs.
Using a conditional knockout mouse, we find that
Satb1 is required for normal differentiation of con-
ventional dendritic cells (DCs). Furthermore, Satb1
governs the differentiation of inflammatory DCs by
regulating major histocompatibility complex class II
(MHC II) expression through Notch1 signaling. Mech-
anistically, Satb1 binds to the Notch1 promoter, acti-
vating Notch expression and driving RBPJ occu-
pancy of the H2-Ab1 promoter, which activates
MHC II transcription. However, tumor-driven, unre-
mitting expression of Satb1 in activated Zbtb46+ in-
flammatory DCs that infiltrate ovarian tumors results
in an immunosuppressive phenotype characterized
by increased secretion of tumor-promoting Galec-
tin-1 and IL-6. In vivo silencing of Satb1 in tumor-
associated DCs reverses their tumorigenic activity
and boosts protective immunity. Therefore, dynamic
fluctuations in Satb1 expression govern the genera-
tion and immunostimulatory activity of steady-state
and inflammatory DCs, but continuous Satb1 overex-
pression in differentiated DCs converts them into tol-
erogenic/pro-inflammatory cells that contribute to
malignant progression.INTRODUCTION
Special AT-rich binding protein 1 (Satb1) is a master genomic
organizer that coordinates gene expression by forming loops in
transcriptionally active chromatin (Cai et al., 2006; Yasui et al.,
2002). Such loops bring enhancers and repressors separated
by long sequences into close proximity with transcriptional start
sites. Because both Satb1 and the DNA-binding zinc-finger pro-
tein CTCF associates with the nuclear matrix, it is likely that they1774 Cell Reports 14, 1774–1786, February 23, 2016 ª2016 The Authinteract to construct the appropriate higher-order chromatin
structure (Lee and Iyer, 2012). Satb1 has been shown to regulate
transcriptional programs by recruiting writers and erasers of
histone modification (Cai et al., 2006; Pavan Kumar et al.,
2006) and DNA methylation, as well as crucial transcription
factors, including b-catenin (Notani et al., 2010). Satb1 therefore
integrates global epigenetic and transcriptional programs that
determine cellular phenotypes, differentiation, and activity of
leukocyte subsets (Borghesi, 2014).
Recently, we found that Satb1 is a direct target of miR-155
in ovarian-associated dendritic cells (DCs) (Cubillos-Ruiz et al.,
2012), which infiltrate solid ovarian tumors (Cubillos-Ruiz et al.,
2009; Huarte et al., 2008; Scarlett et al., 2009, 2012). Although
heterogeneity and phenotypic overlap complicate the categori-
zation of myeloid subsets under inflammatory conditions (Se-
gura and Amigorena, 2013), we demonstrated that when these
leukocytes receive activating signals, they can effectively pro-
cess and present antigens to T cells (Cubillos-Ruiz et al., 2009;
Scarlett et al., 2009). However, in the absence of immunostimu-
latory interventions, tumor-associated DCs are spontaneously
immunosuppressive (Scarlett et al., 2012). One recently identi-
fied mechanism driving the immunosuppressive phenotype of
tumor-associated DCs is the constitutive activation of XBP1 (Cu-
billos-Ruiz et al., 2015). Regulatory ovarian cancer DCs express
significant levels of CD86 and major histocompatibility complex
class II (MHC II) and produce inflammatory pro-tumorigenic cy-
tokines such as IL-6, CCL4, CXCL8, and CCL3 (Cubillos-Ruiz
et al., 2009; Nesbeth et al., 2009; Scarlett et al., 2009). This
phenotype matches the features of DCs indirectly activated by
inflammatory cytokines in the absence of pattern recognition re-
ceptor stimulation (Joffre et al., 2009; Vega-Ramos et al., 2014).
To define the role of Satb1 in the differentiation of DCs in the
steady state and cancer, we generated a conditional Satb1-defi-
cient mice. Our results demonstrate that a dynamic pattern
of Satb1 expression regulates the generation of conventional
DCs as well as the acquisition of MHC II-dependent immuno-
competence by inflammatory DCs through regulation of Notch
signaling. However, unremitting expression in already differenti-
ated DCs drives an inflammatory, immunosuppressive, and tu-
mor-promoting phenotype.ors
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Figure 1. Activated Inflammatory DCs Infil-
trate Syngeneic Ovarian Tumors in Mice
(A) CD45+CD11c+MHC II+ cells in tumor ascites
express Dngr1 and the activation marker CD83.
(B) Zbtb46 transcript levels relative to Gapdh
expression in CD11c+MHC II+ DCs in tumor asci-
tes, total BMDCs at different stages of differenti-
ation, and MHC II+F4/80+ splenic macrophages
from tumor-free mice.
(C) Tumor-associated DCs express phenotypic
markers of inflammatory DCs.
(D) Dngr1+CD11c+MHC II+ DCs are also universally
found in freshly dissociated orthotopic p53-driven
ovarian tumors at days 62 after adenovirus-Cre-
mediated activation of p53 and K-ras mutations.
Representative of four different tumors analyzed.
(E) Western blot analysis of the thymus of wild-type
and Satb1constitutive KO mice define the speci-
ficity of only the lower band.
(F)Western blot comparison of Satb1 expression in
tumor-derived DCs versus BMDCs at different
stages of differentiation.
(G) MHC II expression in tumor-derived (CD45.2+)
CD11c-Cre/Satb1flx/flx versus (CD45.1+) wild-type
CD11c+MHC II+ DCs in mixed BM chimeras chal-
lenged with ID8-Defb29/Vegf-a orthotopic tumors.
Representative of three independent experiments.RESULTS
Activated Inflammatory DCs Universally Infiltrate Solid
Ovarian Tumors in Mice and Humans
We have previously demonstrated that supplementation of miR-
155 toCD11c+DEC205+MHC II+ leukocytes in the ovarian cancer
microenvironment transforms them from an immunosuppressive
toan immunostimulatory cell type throughamechanism involving
silencing of Satb1 (Cubillos-Ruiz et al., 2009). To further define
the phenotype of these cells in established, orthotopic ID8-
Defb29/Vegf-a ovarian tumor-bearing mice, we used markers
specifically expressed by bona fide DCs. As shown in Figure 1A,
most CD11c+MHC II+ leukocytes in tumor ascites expressed the
DC-specific lineage marker Dngr1 (Schraml et al., 2013). Tumor
DCs also expressed the DC-specific transcription factor
Zbtb46 (Meredith et al., 2012; Satpathy et al., 2012), at levels
comparable than CD11c+MHC II+ bone-marrow-derived DCs
(BMDCs) and much higher than F4/80+MHC II+ macrophages in
tumor-free mice (Figure 1B). Tumor-associated CD11c+MHC
II+Dngr1+Zbtb46+ cells co-exhibited FcεRI, CD11b, and CCR7,
phenotypic markers of inflammatory DCs (Segura and Amigor-
ena, 2013). However, the expression of the DC lineage marker
Dngr1 suggests that they are ontogenetically true DCs, rather
than DC-like monocyte-derived cells (Figures 1A and 1C). An
identical (Dngr1+) phenotype was identified in tumor-associated
DCs in orthotopic K-ras-driven solid ovarian carcinomas (Scarlett
et al., 2012) (Figure 1D). Unexpectedly, DCs in tumor ascites also
co-expressed the activationmarker CD83 (Figure 1A). Therefore,
although we have previously demonstrated that they primarily
exert immunosuppressive activities (Cubillos-Ruiz et al., 2009,
2012; Huarte et al., 2008; Scarlett et al., 2009, 2012), bona fide
DCs at ovarian cancer locations represent an activated cell type.Cell RTo define the role of Satb1 in tumor-associated DCs, we
generated conditional Satb1 knockout (KO) mice on a B6 back-
ground. We found that Abcam antibody #EPR3895 produced
two clear bands. However, only the lower band at103 kDa dis-
appeared in thymocytes from constitutive Satb1 KO mice (Fig-
ure 1E) and therefore truly represented Satb1. More importantly,
Satb1 expression levels in CD11c+MHC II+ DCs sorted from tu-
mor ascites were significantly higher than in differentiated
BMDCs, in which Satb1 expression starts decreasing coinciding
with the transition to CD11c+MHC II+ from CD11c+MHC II pre-
cursors (days 5 and 6; Figure 1F). Supporting the role of Satb1
overexpression in mature tumor-associated DCs, congenic
Satb1+ DCs in tumor ascites exhibited higher levels of MHC II
than their CD11c-Cre/Satb1flx/flx DCs in mixed bone marrow
(BM) chimeras (Figure 1G).
Notably, the accumulation of bona fide DCs in ovarian mouse
tumors recapitulates the immunoenvironment of human ovarian
carcinomas, because CD1c+CD11c+MHC II+CD19CD70high
leukocytes (attributes of the human counterpart of inflammatory
DCs; Segura and Amigorena, 2013; Segura et al., 2013) were
found in all freshly dissociated solid advanced tumors samples
analyzed (n = 12), at proportions ranging from 19% to 67% of
total CD45+MHC II+ cells (Figures 2A and 2B). Tumor-infiltrating
human DCs expressed levels of ZBTB46 similar to their counter-
parts in matching peripheral blood or autologous monocyte-
derived DCs (Figure 2C). As with their murine counterparts,
despite showing relatively high expression of co-stimulatory
molecules and MHC II, ovarian cancer-infiltrating DCs from
three randomly selected patients did not elicit allogeneic re-
sponses, while autologous peripheral blood monocyte-derived
DCs induced measurable proliferations (Figure 2D). Taken
together, these results indicate that bona fide DCs universallyeports 14, 1774–1786, February 23, 2016 ª2016 The Authors 1775
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Figure 2. Inflammatory DCs Universally
Infiltrate Solid Human Ovarian Carcinomas
(A) CD45+CD1c+CD11c+HLA-DR+ DCs in four
different dissociated human ovarian carcinomas
(representative of 12 tumors analyzed).
(B) Representative histograms of activation
markers CD70 andHLA-DR in DCs infiltrating three
different human ovarian carcinomas. Gray, isotype
control used in each experiment. Representative of
12 different specimens analyzed.
(C) Zbtb46 mRNA expression relative to GAPDH
expression in tumor-derived DCs (CD45+HLA-
DR+CD11c+CD1c+), tumor-derived macrophages
(CD45+HLA-DR+CD11b+CD1c), peripheral-blood
DCs (CD45+HLA-DR+CD11c+CD1c+), and mono-
cyte-derived DCs from three patients.
(D) Representative mixed lymphocyte reaction
assay performed by co-culturing matched-mono-
cyte or tumor-derived DCs and allogeneic T cells
(left). Proportions of allogeneic T cells proliferating
in response to DCs from three different patients
(right). All data represent mean ± SEM. *p < 0.05,
***p < 0.001.accumulate in the ovarian cancer microenvironment. Although
Satb1 overexpression contributes to their activated phenotype,
DC immunostimulatory function is severely abrogated at tumor
locations.
Satb1 Governs the Generation and Maturation of
Multiple Subsets of Conventional DCs
Tounderstand the role of Satb1 inDCdifferentiation,wenext per-
formed competitive BM reconstitution experiments using BM
from both constitutive and Vav1-Cre-driven Satb1-deficient
mice. As shown in Figure 3A age-matched congenic wild-type
and Satb1 constitutive KO BM showed similar capacity to repo-
pulate total leukocytes in the spleen and also a defect in the
reconstitution of total DCs. Supporting previous reports (Alvarez
et al., 2000), we observed a severe defect in T cell reconstitution
in Satb1-deficient leukocytes (data not shown), compensated by
the expansion of B cells (Figure 3B). We again found a reproduc-
ible decrease in the reconstitution of total splenic DCs arising
from Vav1-Cre-Satb1flx/flx BM, compared to congenic wild-type
progenitors, but this reduction selectively affected conventional
(but not plasmacytoid) DCs (Figure 3C). Satb1 deficiency also
had divergent effects on different subsets of conventional
DCs, causing a significant reduction of overall CD4+ DCs in mul-
tiple experiments, while promoting the relative expansion of
CD11c+CD4CD8B220 DCs (Figure 3D). Interestingly, Satb1
ablation resulted in the elimination of a CD103+CD4+ subset,1776 Cell Reports 14, 1774–1786, February 23, 2016 ª2016 The Authorsboth in the steady state and upon DC
mobilization induced by different cyto-
kines (Figures 3D and 3E).
To dissect the role of Satb1 in the dif-
ferentiation of antigen-presenting cells
(APCs) generated under inflammatory
conditions (Segura et al., 2013), we
treated wild-type and CD11c-Cre/
Satb1flx/flx BM with granulocyte-macro-phage colony-stimulating factor (GM-CSF) in vitro. As shown in
Figure 3F, left, the ablation of Satb1 in lineage-committed
BMDCs triggered by CD11c expression played no significant
role in the acquisition ofMHC I or cross-presentation of SIINFEKL
to OT-1 CD8 T cells when differentiated CD11c+ cells were
pulsed with full-length ovalbumin (OVA) (Figure 3G, left). In
contrast, only a small proportion of Satb1-deficient CD11c+ cells
acquired surface expression of MHC II (Figure 3F, right). Corre-
spondingly, the same Satb1-deficient APCs that effectively pre-
sented antigen through class I failed to stimulate OT-II CD4
T cells (Figure 3G, right). In addition, Satb1-deficient APCs
were unresponsive to Toll-like receptor (TLR)-mediated activa-
tion in termsof upregulation ofMHC II andmultiple co-stimulatory
molecules (Figure 3H). Together, these experiments indicate that
Satb1 plays divergent roles in the differentiation of conventional
DC subsets and contributes to expression of MHC II during in-
flammatory APC differentiation and TLR-dependent increase of
co-stimulatory molecules.
Satb1 Drives the Expression of MHC II on Inflammatory
DCs through a Transient Notch-Signaling-Dependent
Transcriptional Mechanism
Supporting a transcriptional defect, we found significantly lower
H2-Ab1mRNA levels in APCs generated in the absence of Satb1
(Figure 4A). Similar transcriptional differences were obtained
with sorted CD11c+CD135+CD115 cells, specifically derived
Figure 3. Satb1 Influences the Generation and Maturation of Conventional DCs
(A) Mice reconstituted with equal proportions of age-matched wild-type (CD45.1) and constitutive Satb1-deficient BM (CD45.2) analyzed 2 months after
reconstitution.
(B and C) Analysis of spleens frommixed BM chimeras2months after competitive reconstitution with equal ratios of adult age-matched wild-type (CD45.1) and
Vav1-Cre/Satb1flx/flx (CD45.2) BM. Representative of three or more independent experiments with seven or more mice/group.
(D) Reduction of Satb1-deficient total CD4+ and CD4+CD103+ conventional DCs with concomitant expansion of CD4CD8 subsets in the spleen of mixed
wild-type/Vav1-Cre/Satb1flx/flx BM chimeras.
(E) Ablation of Satb1-deficient CD4+CD103+ conventional DCs in response to intraperitoneal administration of Flt3L (10 mg/mouse) and GM-CSF (5 mg/mouse) for
5 consecutive days to induce DC mobilization. Both representative of two or more independent experiments and readouts at day 6.
(F) MHC I and MHC II expression in (CD45.1+) wild-type and (CD45.2+) CD11c-Cre/Satb1flx/flx BMDCs co-cultured for 8 days in the presence of GM-CSF.
Representative of three independent experiments.
(G) Wild-type and CD11c-Cre/Satb1flx/flx BMDCs differentiated for 8 days were pulsed with full-length ovalbumin and incubated with Cell Trace Violet-labeled
OT-I or OT-II T cells. Representative of three independent experiments.
(H) Expression of co-stimulatory markers in (day 9) wild-type and CD11c-Cre/Satb1flx/flx BMDCs after 18 hr incubation with 1 mg/ml lipopolysaccharide.
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Figure 4. Satb1 Drives the Expression of MHC II on the Surface of Differentiated DCs by Regulating Notch1 Signaling
(A) Quantification of H2-Ab1 transcripts relative to Gapdh expression at days 6 and 10 of GM-CSF-induced DC differentiation from Satb1flx/flx and CD11c-Cre/
Satb1flx/flx BM. Representative of three experiments in triplicate.
(B) qPCR quantification ofH2-Ab1mRNA in CD11c+CD135+CD115 cells sorted after 10 days of GM-CSF-induced DC differentiation as in (A). Representative of
two experiments in triplicate.
(C) Ciita expression in Satb1flx/flx and CD11c-Cre/Satb1flx/flx BMDCs at different times of GM-CSF-induced differentiation. Representative of three experiments.
(D) Expression of full-length and intracellular Notch1 during GM-CSF-induced DC differentiation of BM from Satb1flx/flx and CD11c-Cre/Satb1flx/flx. Represen-
tative of three independent experiments.
(E) Dynamics of GM-CSF-induced differentiation of wild-type CD11c+MHC II+ BM cells in these cultures.
(F) Satb1 binding to the Notch1 promoter. Chromatin was immunoprecipitated with anti-Satb1 antibodies (Abs) or control immunoglobulin G (IgG) from
CD11c+APCs differentiated for 7 days with GM-CSF, derived from the BM of wild-type (WT) versus CD11c-Cre/ Satb1flx/flx (KO; control) mice. Enrichment of the
Notch1 promoter sequence in chromatin immunoprecipitated with anti-Satb1 Abs versus irrelevant IgG was quantified by real-time qPCR. Representative of two
independent experiments in triplicate, with similar results.
(G) MHC II expression in CD45+CD11c+ BM cells from either Satb1flx/flx, CD11c-Cre/Satb1flx/flx or RosaNotch mice differentiated with GM-CSF. Representative of
three independent experiments.
(H) Quantification of H2-Ab1 transcripts relative to Gapdh expression at days 6 and 10 of GM-CSF-induced DC differentiation from CD11c-Cre/Satb1flx/flx and
RosaNotch BM. Representative of three experiments.
(I) qPCR of CD11c+ APCs as described above for H2-ab1 promoter sequences in chromatin immunoprecipitated with anti-Rbpj Abs versus irrelevant IgG.
Representative of two independent experiments in triplicate, with comparable results. All data represent mean ± SEM.*p < 0.05, **p < 0.01, and ***p < 0.01.
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from Dngr1+ DC precursors (Helft et al., 2015) (Figure 4B). Sur-
prisingly, we found no Satb1-dependent differences in the
expression levels of Ciita, which controls MHC II transcription
by associating with the basal transcription machinery (Lochamy
et al., 2007) (Figure 4C).
To identify Satb1-dependent regulators of MHC II expression,
we focused on Notch1. Although Notch1 signaling is typically
associated with lymphocytic differentiation, recent studies indi-
cate that Delta-like1-signaling drives cell surface expression of
MHC II in mast cells (Nakano et al., 2009). Accordingly, we found
that at days 6–7 of GM-CSF-differentiation of wild-type BM, pre-
cisely coinciding with the upregulation of MHC II in CD11c+ cells,
Notch expression is elevated in immature myeloid cells and is
progressively downregulated upon terminal differentiation of
APCs (Figures 4D and 4E). This occurs in a Satb1-dependent
manner, because a significant decrease in both full-length
and intracellular Notch1 was identified in nascent APCs upon
CD11c-induced ablation of Satb1.
To determine whether Satb1 physically associates with the
Notch1 promoter, we performed chromatin immunoprecipitation
(ChIP) with specific antibodies, using Satb1/ APCs as a con-
trol. As shown in Figure 4F, we observed significant enrichment
of the Notch1 promoter in Satb1-DNA precipitates from day 7
BM-derived CD11c+MHC II+ APCs, compared to control pull-
downs with an irrelevant immunoglobulin G. Supporting the
specificity of the binding to the Notch1 promoter, no significant
enrichment was found in identically differentiated APCs from
CD11c-Cre/Satb1flx/flx mice (Figure 4F).
Next, we generated triple (CD11c-Cre/Satb1flx/flx/RosaNotch)
transgenic mice and brought them to a B6 background. In this
system, CD11c expression triggers Satb1 ablation while simulta-
neously driving the expression of intracellular (constitutively acti-
vated) Notch1 (Murtaugh et al., 2003) during GM-CSF-induced
differentiation of BM cells into APCs. Supporting the role of
Notch signaling in MHC II transcription, Cre-mediated Notch
activation restored cell-surface expression of MHC II (Figure 4G)
by upregulating H2-Ab1 mRNA levels (Figure 4H). Finally, we
observed significant enrichment of H2-ab1 promoter sequences
in Rbpj-DNA precipitates (but not Hes1-DNA precipitates; data
not shown), indicating that Notch signaling turns on MHC II
through transcriptional activation (Figure 4I). As expected, Rbpj
occupancy of the H2-ab1 promoter decreased significantly in
APCs (Figure 4I). Together, our results unveil a mechanism
whereby Satb1 drives the expression of Notch in APC precursors
(including bona fide pre-DCs) by directly activating the promoter.
By governing MHC II transcription, Notch signaling drives cell-
surface expression of MHC II during APC differentiation,
licensing them for antigen presentation.
Silencing Satb1 in Tumor-Associated DCs Boosts Anti-
tumor Immunity and Delays Malignant Progression
The aforementioned results indicate that Satb1 is required
for full DC differentiation and MHC II-dependent T cell stimula-
tory activity. Correspondingly, CD11c-Cre/Satb1flx/flx BM-re-
constituted mice succumbed to tumor challenge significantly
faster than wild-type BM-reconstituted controls, suggesting
that DCs were incapable of orchestrating protective immunity
(Figure 5A).Cell RTo reconcile the overexpression of Satb1 in tumor DCs
with their immunosuppressive phenotype, we focused on the
fact that, unlike tumor-associated DCs, BMDCs downregu-
late Satb1 after maturation (Figure 1F). We found that inflamma-
tory factors such as S100A8/A9 were sufficient to further
upregulate Satb1 in vivo in DCs in the tumor microenvironment
(TME), while estrogen signaling had the opposite effect (Fig-
ure 5B). To define the effect of inflammation-induced Satb1 over-
expression in already differentiated DCs (as opposed to DC
precursors), we silenced Satb1 specifically in tumor-associated
DCs using small interfering RNA (siRNA)-carrying nanoplexes.
Polyethylenimine (PEI)-based nanoparticles carrying fluores-
cently labeled siRNAwere selectively engulfed byCD11c+ leuko-
cytes at peritoneal (ID8-Defb29/Vegf-a tumor) locations, as we
reported (Cubillos-Ruiz et al., 2009, 2012) (Figure 5C). Satb1-tar-
geting, but not control (non-targeting), nanoparticles effectively
silenced Satb1 expression in vivo in ovarian cancer DCs (Fig-
ure 5D) and, accordingly, induced Notch1 downregulation.
Most importantly, silencing Satb1 throughout the course of ma-
lignant progression significantly enhanced anti-tumor immunity,
as determined by both Granzyme B and IFN-g ELISPOT analysis
(Figure 5E). Accordingly, the accumulation of antigen-experi-
enced (CD44+) cytotoxic T cells exhibiting markers of recent
activation was also significantly increased upon Satb1 silencing
(Figure 5F). Furthermore, OT-I T cells responded significantly
more strongly to cognate antigen in situ in the ovarian cancer
microenvironment when Satb1-silenced tumor DCs were pulsed
in vivo with full-length OVA, compared to DCs identically pulsed
in mice treated with irrelevant nanoparticles (Figures 5G and 5H).
Supporting the relevance of enhanced protective immunity,
repeated Satb1 silencing specifically in DCs resulted in signifi-
cantly longer survival rates, compared to control irrelevant siRNA
nanocomplexes (Figure 5I). Therefore, inflammatory cytokines in
the TME upregulate Satb1, resulting in an immunosuppressive,
tumor-promoting phenotype.
Satb1 Governs Genome-wide Transcriptional
Modifications
To define the spectrum of transcriptional changes induced by
Satb1 overexpression, we treated mice with ovarian cancer-
induced ascites with fluorescently labeled Satb1-specific versus
non-targeting PEI-based nanocomplexes. After 20–24 hr,
CD11c+MHC II+ DCs targeted by functional Satb1-specific or
identically delivered control siRNA were collected and subjected
to RNA deep-sequencing. In the first experiment, mRNA of
Satb1 was reduced 4.8-fold and overall, 1,003 genes changed
their expression by at least 50% (Data S1). In the second exper-
iment, when Satb1 reduced expression only by 20%, we found
521 genes that significantly changed expression with any fold
(Data S1). Significant overlap between the two sets of 72 genes
(Figure 6A, p = 3 3 1011 by hypergeometric test) indicates that
there is a subset of genes sensitive to Satb1 expression even
when the expression changes are very small. The full list of 72
genes significantly up- and downregulated with any level of
Satb1 changes in both experiments, which includes an array of
inflammatory cytokines and chemokines, is shown in Figure 6B.
In addition, Ingenuity Pathway Analysis of the 1,003 genes that
underwent expression change of at least 1.5-fold upon Satb1eports 14, 1774–1786, February 23, 2016 ª2016 The Authors 1779
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Figure 5. Silencing Satb1 in Tumor-Associ-
ated DCs Boosts Anti-tumor Immunity and
Delays Malignant Progression
(A) Survival of mice reconstituted with wild-type
versusCD11c-Cre/Satb1flx/flxBMafter ID8-Defb29/
Vegf-a tumor challenge. Two independent experi-
ments pooled (9–10 mice/group).
(B) Mice bearing ID8-Defb29/Vegf-a tumor ascites
receivedS100A9 (25mg) or b-estradiol (0.01mg) i.p.
CD11c+MHC II+ DCs were FACS-sorted and
analyzed for Satb1 expression 34–48 hr later.
Representative of three independent experiments.
(C) Rhodamine-labeled Satb1-targeting siRNA-PEI
nanoparticles were i.p. injected into 3-week ID8-
Defb29/Vegf-a tumor-bearing mice. Rhodamine+
DCs were identified 36 hr later.
(D) Satb1 andNotch1expression inCD11c+MHC II+
DCs sorted from tumor ascites 36–48 hr after i.p.
administration of non-targeting (NT) or Satb1-tar-
geting siRNA-PEI (F.l., full-length, I.C., intracellular).
(EandF)Mice received indicated treatmentsatdays
8, 13, 18, 23, and 28 after tumor challenge. T cells
from ascites were used for IFN-g- and Granzyme
B-ELISPOT analysis (E) or expression of CD44 and
CD69 levels (F). Representative of two independent
experiments (four to six mice per group).
(G) ID8-Defb29/Vegf-a tumor-bearing mice treated
for 3 weeks with siRNA-carrying nanocomplexes
or PBS received 0.6 mg full-length endotoxin-
free ovalbumin i.p. 3 hr after the last treatment, fol-
lowed 18 hr later by i.p. transfer of 2 ± 106 carbox-
yfluorescein succinimidyl ester (CFSE)-labeled
SIINFEKL-specific OT-1 T cells. Peritoneal wash
was collected after 48 hr and CFSE dilution was
quantified. Representative of three independent
experiments (six mice per group).
(H) Division Index of proliferating cells in (F).
(I) ID8-Defb29/Vegf-a tumor-bearing mice received
five treatments every 5 days andweremonitored for
survival. Data represent two independent experi-
ments with ten mice total per group. All data
represent the mean ± SEM. *p < 0.05, **p < 0.01,
and ***p < 0.001.silencing of 4.8-fold in tumor-associated DCs revealed many
signaling pathways affected in Satb1-overexpressing cells (Fig-
ure 6C). Inflammatory networks driven by Satb1 overexpression
included Il6-mediated pathways and pathways for granulocyte
and agranulocyte adhesion and diapedesis. Upstream regulator
analysis revealed multiple regulators affected by Satb1 (Fig-
ure 6D) as estimated frommRNA changes in their known targets.
For example, Ifnb1 and Tnf, in which mRNA levels were most
significantly altered, were indeed functionally more active with
Satb1 overexpression, as 38 targets for Ifnb1 and 139 targets
for Tnf displayed significant mRNA changes, indicative of the
regulators’ activation.
In accordance with results of pathway analysis, Il6 target
genes demonstrated that Il6 was more active when Satb1 was
present. Supporting our in vitro results, we also observed similar
effects on Notch1 signature and, interestingly, an Lgals1 signa-1780 Cell Reports 14, 1774–1786, February 23, 2016 ª2016 The Authture. Galectin-1, encoded by the Lgals1 gene, is a pleiotropic
protein that binds to surface glycoconjugates containing N-ace-
tyllactosamine sequences, cross-linking these saccharide struc-
tures on immune cells and driving potent immunosuppression
(Dalotto-Moreno et al., 2013; Rubinstein et al., 2004; Rutkowski
et al., 2015; Toscano et al., 2007). Together, these data indicate
that unremitting overexpression of Satb1 in already differenti-
ated inflammatory DCs in the TME drives genome-wide tran-
scriptional changes that globally affect the transcriptome and
promotes an immunosuppressive phenotype.
Satb1-Dependent Secretion of Galectin-1 Is Sufficient
to Accelerate Tumor Progression
Substantiating the relevance of our genomic analysis, fluores-
cence-activated cell sorting (FACS)-sorted DCs engulfing
Satb1-silencing nanocomplexes secreted significantly lowerors
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levels of both IL-6 and galectin-1, compared to non-targeted
siRNA-untreated controls (Figure 7A). Correspondingly, en-
forced retroviral-mediated expression of Satb1 augmented
their production of both galectin-1 and tumor-promoting IL-6
(Figure 7B).
We have previously identified galectin-1 as amajor pathogenic
factor in a variety of tumors (Rutkowski et al., 2015). To determine
the relevance of Satb1-dependent upregulation of galectin-1
specifically in tumor microenvironmental DCs, we ectopically
overexpressed Satb1 in wild-type and galectin-1-deficient
BMDCs, independently admixed them with tumor cells, and
used the mixture to challenge different cohorts of naive mice.
As shown in Figures 7C and 7D, these slowly progressing tumors
grew significantly faster when admixed with Satb1-overexpress-
ing wild-type DCs, compared to mock-transduced control
DCs. However, Satb1-dependent acceleration of tumor growth
(versus the administration of tumor cells without DCs) only
occurred when tumor-associated DCs had the capacity to
upregulate galectin-1 (Figure 7C). Importantly, galectin-1-defi-
cient BMDCs showed the same differentiation kinetics as their
wild-type counterparts (Figure 7E). Similarly, when tumor cells
were admixed with Satb1-transduced IL-6/ DCs, they still
grew significantly faster than tumors containing mock-trans-
duced IL-6/DCs, but significantly more slowly than tumors ad-
mixedwithSatb1-transducedwild-typeDCs (Figures 7F and 7G).
Together, these results indicate that Satb1 unrelenting overex-
pression drives complex tumor-promoting, pro-inflammatory ac-
tivities in tumor-associatedDCs, forwhich the secretion of immu-
nosuppressive galectin-1 and IL-6 are significant contributors.
DISCUSSION
We find that Satb1 governs a genome-wide transcriptional pro-
gram required for terminal steady-state DC differentiation and
effective antigen presentation through MHC II. Paradoxically,
Satb1 needs to be extinguished after DCmaturation for effective
immunostimulatory activity. Accordingly, unremitting expression
of Satb1 in fully committed inflammatory DCs in solid ovarian tu-
mors drives an immunosuppressive cell type that outnumbers
canonical macrophages and contributes to accelerate malignant
progression.
Inflammatory TLR signals appear to be necessary to activate
DCs for effective T cell priming, but cytokines such as interleukin
1b (IL-1b), tumor necrosis factor (TNF), or type I interferons can
activate DCs in an alternative manner. Although these inflamma-
tory cytokines induce DC maturation, they are not sufficient to
generate T cell stimulatory DCs. Thus, DCs that were activated
by cytokines in the absence of TLR agonists do not efficientlyFigure 6. Transcriptional and Regulatory Changes Caused by Satb1 O
(A) Numbers of significantly changed genes and their overlap between two indepe
overlap was 2.7 more than expected by random chance alone (p = 3 3 1011 by
(B) Expression heatmap and fold changes for 72 genes affected by high and low le
Satb1 indicate Satb1-siRNA treated samples.
(C) Canonical pathways significantly affected by Satb1 overexpression. Il6-medi
diapedesis were among the most significantly affected and were highlighted to d
(D) Predicted upstream regulators whose regulatory function was significantly a
target genes.
1782 Cell Reports 14, 1774–1786, February 23, 2016 ª2016 The Authprime effector T cell responses and are regarded as poor stimu-
lators of T cell-mediated immunity (Joffre et al., 2009). Inflamma-
tion, therefore, does not substitute for pattern recognition
receptor signaling, but it does alter the nature and magnitude
of cytokines secreted by DCs. Cytokine-activated DCs, for
instance, produce much higher amounts of IL-6, CCL3, or
CCL4 in response to TLR activation, compared to their immature
counterparts (Vega-Ramos et al., 2014).
Unlike other tumors that accumulate immature myeloid pro-
genitors but few mature DCs, we have previously identified acti-
vated bona fide inflammatory DCs as an abundant population in
themicroenvironment of solid ovarian carcinomas (Cubillos-Ruiz
et al., 2009; Huarte et al., 2008; Scarlett et al., 2009, 2012). Their
DC nature is supported by the expression of Zbtb46 transcripts
(Meredith et al., 2012; Satpathy et al., 2012). Additionally, ovarian
cancer DCs can be induced to process full-length OVA in vitro
(Conejo-Garcia et al., 2004) and in vivo (Cubillos-Ruiz et al.,
2009; Scarlett et al., 2009) to present processed SIINFEKL
to T cells. Although inflammatory DCs are thought to originate
from monocytes (Segura and Amigorena, 2013), murine ovarian
cancer DCs express the DC lineage marker Dngr1 (Schraml
et al., 2013), suggesting that they may alternatively arise from
DC precursors. Their mature phenotype suggests a role for indi-
rect inflammatory activation in the acquisition of a tumor-pro-
moting phenotype by ovarian-cancer-associated DCs (Huarte
et al., 2008; Scarlett et al., 2012). Supporting this proposition,
we found that S100A8/A9 proteins upregulate Satb1 in DCs
in vivo and in vitro and that Satb1 expression enhances the
secretion of inflammatory cytokines and chemokines by DCs.
Accordingly, silencing Satb1 expression selectively in tumor-
associated DCs in vivo at tumor locations reduced the level of
inflammation and immunosuppression in the TME and boosted
T cell-mediated immune protection. Notably, 22% of transcripts
underwent R2-fold changes in expression levels upon Satb1
knockdown. Therefore, consistent with its role as a master
genomic organizer, Satb1 drives major phenotypic changes
that are sufficient to accelerate malignant progression and sup-
press anti-tumor immunity. Although this study cannot segre-
gate the precise contribution of Satb1-dependent loop formation
to the entire range of genome-wide effects, it is likely that these
dramatic phenotypic changes are the result of both looping and
transcriptional activator/repressor activities. Of note, although
Satb1 is highly similar to Satb2 and both regulate chromatin re-
modeling and gene regulation, the latter is not expressed in
BMDCs (not shown), and therefore all observed effects can
only be attributed to Satb1.
Among the spectrum of Satb1-dependent mechanisms, we
identified the direct activation of the Notch1 promoter as a driververexpression
ndent experiments that changed expression of Satb1 4.8-fold and 1.2-fold. The
hypergeometric test).
vels of Satb1 change. N and NT indicate NT siRNA-treated samples, and S and
ated pathways and pathways for granulocyte and agranulocyte adhesion and
emonstrate expression changes of individual genes in the pathway.
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Figure 7. Satb1 Overexpression of Tumor DCs Accelerates Malignant Progression by Promoting the Secretion of IL-6 and Galectin-1
(A) ELISA quantification of galectin-1 and IL-6 released by phorbol 12-myristate 13-acetate (PMA)/ionomycin (500 ng/1 mg/ml)-stimulated CD11c+MHC II+ DCs
sorted from day 35 tumor ascites, 20–24 hr after treatment with 100 mg of Rhodamine-labeled NT or Satb1-targeting siRNA-carrying polyplexes. Pooled from
two independent experiments.
(B) GM-CSF-differentiated wild-type BM cells were transduced at days 2 and 3 with empty or Satb1-encoding retroviruses. Galectin-1 and IL-6 quantified in
supernatants of PMA/ionomycin-stimulated mock- or Satb1-transduced BMDCs. Pooled from two independent experiments in triplicate.
(C) Wild-type and Lgals1/ BMDCs were transduced with Satb1 or the empty retrovirus and admixed (1:10 ratio) with 106 ID8-Defb29/Vegf-a cells for injection
into the axillary flank. Tumor growth was monitored. With the exception of tumor cells alone and mock transduced Lgals1/ DCs, representative of three
independent experiments (five or more mice per group).
(D) Tumor weight and size comparison of tumors resected at day 55 in one of the experiments.
(E) Comparable proportions of CD11c+MHC II+ DCs generated from wild-type and Lgals1/ BM after 9 days of culture with GM-CSF. Representative of three
independent experiments.
(F) Mice (5/group) were challenged with ID8-Defb29/Vegf-a tumors admixed with Satb1/mock-transduced wild-type versus Il6/ BMDCs as in (C), and tumor
growth was monitored.
(G) Tumor weight and size comparison of tumors resected at day 55. All data represent the mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001.of terminal inflammatory DC differentiation. Notch1 is transiently
upregulated during the switch from CD11c+MHC II to
CD11c+MHC II+ APCs. Using genetically engineered systems,Cell Rour data indicate that ectopic expression of Notch is sufficient
to restore MHC II surface expression in the absence of Satb1,
through a transcriptional mechanism dependent on directeports 14, 1774–1786, February 23, 2016 ª2016 The Authors 1783
binding of Rbpj to the H2-Ab1 promoter. Although seminal
studies by the Gabrilovich lab had previously identified a role
for Notch in DC differentiation (Zhou et al., 2009), the require-
ment of Notch signaling for the acquisition of MHC II immuno-
competence in inflammatory DCs is surprising and opens
avenues to understanding how transient Notch signaling could
contribute to emergency myelopoiesis.
Finally, our study identifies galectin-1, an immunosuppressive
lectin, as a major target of Satb1 in tumor-associated DCs. As
galectin-1 coordinates tolerogenic programs in human and
mouse DCs (Ilarregui et al., 2009), limits survival of Th1 and
Th17 cells (Toscano et al., 2007), and promotes the differentia-
tion of tumor Foxp3+ T regulatory cells (Dalotto-Moreno et al.,
2013), our findings suggest that Satb1 may contribute to tumor
progression by hierarchically activating galectin-1-driven cancer
immune-evasive pathways. The dramatic effect that Satb1-
dependent, DC-derived galectin-1 production in nascent tumors
has on subsequent tumor growth supports the relevance of this
mechanism. Overall, our results show an alternative Satb1-
driven mechanism that controls DC function in healthy condi-
tions and cancer.EXPERIMENTAL PROCEDURES
Mice and Cell Lines
Satb1 transgenic mice used in this work were generated by Wistar’s Mouse
Transgenic Facility with clones of embryonic stem cells carrying a targeted/
floxed version of Satb1 procured fromEUCOMMand injected into blastocysts.
The resulting heterozygous colony founders were crossed with C57BL/6
breeders to confirm parental transmission of the targeted version of Satb1,
genotyped for loxP and LacZ and further crossed until homozygosis to obtain
aSatb1 full KOmice. Complete absence of Satb1 expression in Satb1 KOmice
was verified by western blot in the thymus, an abundant source of Satb1
expression. To be able to specifically ablate Satb1 expression in certain cell
compartments, Satb1floxed/wt mice were crossed with the deleter strain
ACTFLPe (stock #003800, Jackson Laboratory) that express the FLP recombi-
nase under the direction of the ACTB promoter to ubiquitously delete the FRT-
flanked sequence. Successively, Satb1floxed/floxed mice were crossed with
either CD11c-Cre (Jackson Laboratory #008068) or Vav1-Cre (Jackson Labo-
ratory #008610) mice.
Notch1-Rosa26 mice were kindly provided by Dr. B.Z. Stanger (University of
Pennsylvania Perelman School of Medicine) and backcrossed for at least ten
generations to a C57BL/6 background. These transgenic mice have a floxed
version of Notch1 interrupted by a STOP codon at the permissive locus
Rosa26. Notch1-Rosa26 mice were crossed with Satb1floxed/floxed CD11c-
Cre-recombinase to obtain conditional triple transgenic mice that simulta-
neously overexpress Notch1 and ablate Satb1 expression in the CD11c
compartment.
Galectin-1-deficient (Lgals1/) mice were originally generated by F. Poi-
rier (Jacques Monod Institut, Paris). OT-I and OT-II transgenic mice were
purchased from Taconic. C57BL/6 and congenic CD45.1+ mice (5–6 weeks
old) were purchased from the Frederick Cancer Research Facility at
the NCI.
All animals were maintained in pathogen-free barrier facilities. All experi-
mental procedures were conducted in agreement with the institutional animal
care and use committee of the Wistar Institute.
Parental ID8 cells were provided by K. Roby (Department of Anatomy and
Cell Biology, University of Kansas Medical Center, Kansas City, KS) (Roby
et al., 2000) and retrovirally transduced to express Defb29 and Vegf-a (Con-
ejo-Garcia et al., 2004). Flank tumors with ID8-Defb29-Vegf-a cells were
admixed at a 10:1 ratio with BMDCs using factor-reducedMatrigel (BD Biosci-
ences) and injected into the axillary flank. Tumor volume was calculated using
the following equation: (L3W2)/2, where L is length and W is width. For retro-1784 Cell Reports 14, 1774–1786, February 23, 2016 ª2016 The Authviral transduction of Satb1, virus-containing media was produced transfecting
the ecotropic Phoenix retroviral packaging cell line (Allele Biotech).
Mice bearing ID8-Defb29/Vegf-a tumors for 32–35 days were intraperitone-
ally (i.p.) injected with S100A9 (25 mg/mouse; Fitzgerald). After 36–48 hr, sorted
tumor-associated DCs were analyzed for Satb1 expression as indicated.
Human Specimens
Advanced (stage III–IV) human ovarian carcinoma tissues were freshly pro-
cured under a protocol approved by the institutional review boards at Christi-
ana Care Health System (#32214) and The Wistar Institute (#21212263).
Informed consent was obtained from all subjects. Tumors were mechanically
dissociated and directly analyzed or cryopreserved as viable single-cell sus-
pensions for future analysis.
Generation of Bone Marrow Chimeras
Mononuclear BM cells collected from adult age-matched CD45.1 (congenic)
wild-type or CD45.2 Satb1/ donor mice (1–23 106) were mixed in a 1:1 ratio
and retro-orbitally injected into lethally irradiated (950 rad) adult recipients.
Mixed chimeras were analyzed after 7–8 weeks as indicated.
Antigen Presentation
For in vitro experiments, CD11c+MHC II+ sorted BMDCs (day 7) were incu-
bated with 50 mg/ml full-length OVA (Sigma-Aldrich) for 3–15 hr, thoroughly
washed, and co-cultured with Cell Trace Violet (Life Technologies)-stained
OT-I or OT-II isolated T cells in a 1:10 ratio for 65–75 hr. T cell proliferation
was analyzed by FACS on the basis of Cell Trace Violet and CD3+CD8b+ or
CD3+CD4+, respectively. Division index was calculated by FlowJo.
Retroviral Transduction
Murine Satb1 cDNA (Source Bioscience) was subcloned into the retroviral
expression vector pBMN-I-GFP (Addgene). BM cells were isolated from
wild-type or Lgals1/mice and cultured as with GM-CSF for BMDC differen-
tiation. At days 2 and 3 of culture, cells were washed and resuspended inMock
or Satb1 pBMN virus-containing media supplemented with 8mg/ml Polybreen
(Millipore). Cells were then spin-infected at 2,500 rpm for 2 hr at 32C, and the
media was renewed 18 hr later. After 4 days of viral transduction, BMDCswere
FACS sorted for GFP+CD11c+ and tested for different readouts as indicated.
In Vivo Delivery of PEI-siRNA Nanoparticles/Satb1 Silencing
Selective in vivo targeting of Satb1 in tumor-associated DCs was previously
described (Cubillos-Ruiz et al., 2009, 2012). In brief, murine on-Targeting
(Ambion) or Satb1 (Ambion or Integrated DNA Technologies) siRNA-polyethy-
lenimine nanocomplexes were administered i.p. to mice bearing ID8-Defb29/
Vegf-a tumors, using endotoxin-free ‘‘in vivo-Jet-PEI’’ FluoR at anN/P ratio of 6
following the recommendations of the manufacturer (Polyplus Transfection).
For survival, ELISPOTs, and phenotypic and antigen presentation experi-
ments, ID8-Defb29/Vegf-a-challenged mice were i.p. treated with 50 mg
siRNA-PEI nanocomplexes on days 8, 13, 18, 23, and 28 after tumor challenge.
Survival wasmonitored periodically from this time point. For phenotypic exper-
iments, total cells were obtained from red blood cell lysed peritoneal washes of
siRNA-PEI-treated tumor-bearing mice 24 hr after the last treatment and
analyzed by flow cytometry. Alternatively, total peritoneal cells were co-
cultured for 48 hr, in coated and blocked ELISPOT plates with BMDCs
(day 7) in a 10:1 ratio, which were previously pulsed (overnight) with gamma-
and UV-irradiated ID8-Defb29/Vegf-a cells (10 DCs:1 tumor cell). Analysis
for IFN-g and Granzyme B spots was performed according to the manufac-
turer’s protocol (eBioscience).
To test antigen presentation capabilities of tumor-associated-DCs in vivo,
mice bearing ID8-Defb29/Vegf-a for 25–30 days were i.p. injected with
0.6 mg full-length OVA. After 3 hr, mice were either left untreated or injected
i.p. with non-targeting or Satb1 siRNA-PEI nanocomplexes. Then, negatively
isolated carboxyfluorescein succinimidyl ester (CFSE)-labeled CD3+ OT-I
splenocytes (23 106/mouse) were injected i.p. 18 hr after the siRNA treatment.
48 hr later, CD3+CFSE+OT-I+ cells were harvested from peritoneal cavity and
analyzed by FACS for proliferation.ors
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